Equities Analysts Set Expectations for OPKO Health, Inc.’s Q2 2021 Earnings (NASDAQ:OPK)


Share on StockTwits

OPKO Health, Inc. (NASDAQ:OPK) – Investment analysts at Jefferies Financial Group lowered their Q2 2021 earnings per share estimates for shares of OPKO Health in a research report issued to clients and investors on Thursday, April 29th. Jefferies Financial Group analyst M. Raycroft now expects that the biotechnology company will post earnings of $0.03 per share for the quarter, down from their prior forecast of $0.04. Jefferies Financial Group also issued estimates for OPKO Health’s FY2021 earnings at ($0.01) EPS and FY2025 earnings at $0.39 EPS.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings data on Wednesday, April 28th. The biotechnology company reported $0.05 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.05. OPKO Health had a negative net margin of 9.79% and a negative return on equity of 2.61%.

Separately, Barrington Research increased their price objective on shares of OPKO Health from $7.00 to $8.00 and gave the company an “outperform” rating in a research report on Friday, February 19th.

Shares of OPKO Health stock opened at $3.96 on Monday. The firm has a market capitalization of $2.65 billion, a P/E ratio of -22.00, a PEG ratio of 5.84 and a beta of 1.98. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.13. The company has a 50 day moving average price of $4.37 and a 200 day moving average price of $4.44. OPKO Health has a 52 week low of $1.91 and a 52 week high of $6.47.

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 500,000 shares of the business’s stock in a transaction that occurred on Friday, February 19th. The shares were bought at an average price of $4.77 per share, for a total transaction of $2,385,000.00. Following the acquisition, the chief executive officer now owns 3,068,951 shares in the company, valued at $14,638,896.27. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 40.90% of the stock is currently owned by corporate insiders.

Large investors have recently modified their holdings of the stock. Matrix Asset Advisors Inc. NY acquired a new position in OPKO Health in the 4th quarter worth approximately $40,000. Beacon Pointe Advisors LLC acquired a new stake in shares of OPKO Health during the 4th quarter worth approximately $40,000. Clear Harbor Asset Management LLC grew its stake in shares of OPKO Health by 10,000.0% during the 4th quarter. Clear Harbor Asset Management LLC now owns 10,100 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 10,000 shares during the period. Linscomb & Williams Inc. purchased a new position in shares of OPKO Health during the 4th quarter valued at approximately $43,000. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of OPKO Health in the 4th quarter valued at $51,000. Institutional investors own 28.51% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services.

Further Reading: NASDAQ

Earnings History and Estimates for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.